Prometheus Biosciences, Inc. (NASDAQ: RXDX)

Engel Law PLLC is investigating whether fair value to Prometheus shareholders will result from the proposed acquisition of Prometheus Biosciences, Inc. (NASDAQ: RXDX) by Merck (NYSE: MRK) for $200 in cash for each Prometheus share.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Prometheus Biosciences, Inc.

MM slash DD slash YYYY